MétaCan
Menu
Back to cohort
Record W2279192913

Vinorelbine liposomes injection results in greater tumor drug exposure compared to conventional vinorelbine in tumor-bearing nude mice

2007· article· en· W2279192913 on OpenAlexaff
Steven R. Deitcher, Pieter R. Cullis, May Q. Wong, Gavin Choy

Bibliographic record

VenueMolecular Cancer Therapeutics · 2007
Typearticle
Languageen
FieldMedicine
TopicCancer Treatment and Pharmacology
Canadian institutionsUniversity of British Columbia
Fundersnot available
KeywordsVinorelbinePharmacokineticsPharmacologyLiposomeChemistryVolume of distributionInternal medicineMedicineChemotherapyBiochemistry
DOInot available

Abstract

fetched live from OpenAlex

C109 Background: Conventional vinorelbine tartrate (VRL) is a lipophilic, cell-cycle-specific anticancer agent that inhibits tumor cell growth by disrupting microtubule assembly during metaphase. AlocrestTM (vinorelbine liposomes injection) is a proprietary sphingomyelin/cholesterol liposome (OPTISOMETM) encapsulated formulation of VRL with an extended circulating half-life and the potential for enhanced tumor tissue targeting, exposure, and antitumor activity. This study evaluated and compared the pharmacokinetic (PK) profiles and tissue distributions (TD) of Alocrest and VRL in tumor-bearing CD-1 female nude mice. Methods: Mice were subcutaneously implanted with MX-1 human breast tumors. When tumor volumes reached 150 mm3,twenty-four mice per group received a single IV bolus dose of 20 mg/kg (60 mg/m2) of either VRL (3H-VRL) or Alocrest (3H-Alocrest) via the tail vein in a vehicle volume of 10 µL/g body weight. Blood/plasma and tissue samples (gall bladder/bile, heart, kidneys, liver, lungs, muscle, ovaries, small intestine, spleen, and tumor) were collected at 5 min, 1 h, 4 h, 8 h, 24 h, and 96 h post dosing. The total radioactivity from parent compound and metabolites in tissue, VRLeq, was analyzed by liquid scintillation counting. Results: The concentrations of VRLeq in blood/plasma were higher after administration of Alocrest resulting in higher AUCinf in Alocrest-treated mice compared to VRL-treated mice. The steady state volume of distribution and clearance were lower for Alocrest compared to VRL, supporting slower distribution and removal of Alocrest from the plasma compartment. The TD profile of Alocrest showed that, depending on the tissue, VRLeq concentrations peaked at 4 or 8 hours compared to VRL Tmax at 5 minutes or 1 hour. Tumor AUClast values (h*mcg/g) for VRLeq were 1166 in the Alocrest group and 123 in the VRL group. The AUClast for Alocrest was 9.5-fold greater in the tumor, 7.0-fold higher in spleen, 2.4-fold higher in ovaries and 1.0-1.6-fold higher in most other tissues (lower in lung) compared to the AUClast for conventional VRL. The greatest amount of radioactivity as a percent of injected dose (%ID) following Alocrest was found in liver > spleen > tumor while following VRL the greatest %ID was in liver > kidneys > lungs > small intestine. The %ID following Alocrest peaked at 4 to 8 hours before declining except in tumor where %ID peaked at 24 hours and remained constant for up to 96 hours. Conclusions: Optisomal encapsulation of VRL, Alocrest, protects the drug from initial rapid distribution observed with conventional VRL and provides longer drug retention in the circulation. Alocrest results in targeted delivery of drug, accumulation of drug in tumor tissue, and gradual drug release over several days. These unique characteristics result in greater tumor drug exposure and the potential for enhanced anti-tumor activity without increased toxicity. Human clinical trials are ongoing at this time.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.168
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.027
GPT teacher head0.322
Teacher spread0.296 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2007
Admission routes1
Has abstractyes

Explore more

Same venueMolecular Cancer TherapeuticsSame topicCancer Treatment and PharmacologyFrench-language works237,207